OncoMatch/Clinical Trials/NCT07469891
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Is NCT07469891 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies PRT12396 for polycythemia vera (pv).
Treatment: PRT12396 — This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE\[s\]). The study consists of a dose-escalation phase followed by a dose-expansion phase to further evaluate selected dose level(s).
Check if I qualifyExtracted eligibility criteria
Cancer type
Myeloproliferative Neoplasm
Biomarker criteria
Required: JAK2 v617 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy for PV or MF
Prior systemic therapy for PV or MF
Cannot have received: allogeneic hematopoietic stem-cell transplantation
Exception: prior or planned
prior or planned allogeneic hematopoietic stem-cell transplantation
Cannot have received: splenectomy
prior splenectomy
Cannot have received: splenic irradiation
prior splenic irradiation
Cannot have received: hematopoietic growth factors
Exception: within protocol-defined washout periods
use of hematopoietic growth factors within protocol-defined washout periods
Lab requirements
Blood counts
adequate bone marrow reserves (hematology)
Kidney function
adequate renal function
Liver function
adequate hepatic function
Adequate organ function and bone marrow reserves (hematology, renal, and hepatic)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- START Midwest, LLC · Grand Rapids, Michigan
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify